Emergent BioSolutions to Participate in First Quarter 2018 Investor Conferences

GAITHERSBURG, Md., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the first quarter of 2018:

• J.P. Morgan & Co. – 36^th Annual Healthcare Conference
  San Francisco, CA
  January 8-11, 2018
  
  

• RBC Capital Markets – 2018 Global Healthcare Conference
  New York, NY
  February 21-22, 2018
  
  

• Cowen & Co. – 38^th Annual Health Care Conference
  Boston, MA
  March 12-14, 2018

Presentation dates and times will be updated on the Emergent website www.emergentbiosolutions.com under “Investors” as the information becomes available.

For these conferences, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website.

About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
[email protected]

Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
[email protected]

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• JPMorgan Downgrades Spire (SR) to Neutral
• Stifel cuts Microsoft target, says Street FY27 gross margin estimates are too high